Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 4/20 | 0.40 |
| ▸ | BTK | Q06187 | 7/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | LYN | P07948 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | BLK | P51451 | 2/20 | 0.38 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TEC | P42680 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607695 | 1.00 | AURKB (0.40) | AURKBAURKABTKBRAFKDR | |
| SCHEMBL15221982 | 0.91 | AURKA (0.44) | AURKBAURKAKDRKITLCK | |
| SCHEMBL3618246 | 0.89 | AURKB (0.42) | AURKBAURKABTKKDRKIT | |
| SCHEMBL3624534 | 0.89 | KDR (0.50) | AURKBAURKABTKKDRKIT | |
| SCHEMBL3624532 | 0.89 | KDR (0.50) | AURKBAURKABTKKDRKIT | |
| SCHEMBL276371 | 0.88 | BRAF (0.45) | AURKBAURKABTKBRAFKDR | |
| SCHEMBL3614890 | 0.86 | BRAF (0.40) | AURKBAURKABTKBRAFKDR | |
| SCHEMBL14416196 | 0.85 | AURKB (0.44) | AURKBAURKABTKKDRKIT | |
| SCHEMBL3617195 | 0.84 | AURKB (0.43) | AURKBAURKABTKKDRKIT | |
| SCHEMBL3620700 | 0.84 | AURKB (0.44) | AURKBAURKABTKKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8338595-B2 | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1765823-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORP (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7563791-B2 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1765823-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121147-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | AURKB 2267/4885AURKA 1525/4885BTK 4368/4885 |
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | AURKB 2267/4885AURKA 1525/4885BTK 4368/4885 |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | MKI67, CCNA1, CCNI | AURKB 1447/4885AURKA 510/4885BTK 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.